Andri Rauch

List of Publications by Year
in descending order

171 papers	8,138 citations	57758 44 h-index	56724 83 g-index
185 all docs	185 docs citations	185 times ranked	10237 citing authors

#	Article	IF	Citations
1	Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology, 2010, 138, 1338-1345.e7.	1.3	1,056
2	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet, The, 2019, 393, 2428-2438.	13.7	627
3	Early and nonreversible decrease of CD161++/MAIT cells in HIV infection. Blood, 2013, 121, 951-961.	1.4	307
4	Prospective Genetic Screening Decreases the Incidence of Abacavir Hypersensitivity Reactions in the Western Australian HIV Cohort Study. Clinical Infectious Diseases, 2006, 43, 99-102.	5.8	301
5	Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic. Clinical Infectious Diseases, 2012, 55, 1408-1416.	5.8	225
6	Unsafe Sex and Increased Incidence of Hepatitis C Virus Infection among HIV-Infected Men Who Have Sex with Men: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2005, 41, 395-402.	5.8	203
7	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. Journal of Clinical Investigation, 2011, 121, 2391-2400.	8.2	168
8	Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. Aids, 2008, 22, 2135-2141.	2.2	145
9	Determinants of HIV-1 broadly neutralizing antibody induction. Nature Medicine, 2016, 22, 1260-1267.	30.7	133
10	Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. Hepatology, 2009, 49, 1069-1082.	7.3	131
11	Role of retroviral restriction factors in the interferon-Î±â€“mediated suppression of HIV-1 in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3035-3040.	7.1	129
12	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. Clinical Infectious Diseases, 2011, 52, 532-539.	5.8	127
13	Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. Aids, 2011, 25, 399-409.	2.2	126
14	A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. ELife, 2013, 2, e01123.	6.0	126
15	2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. HIV Medicine, 2020, 21, 617-624.	2.2	115
16	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nature Communications, 2019, 10, 3193.	12.8	112
17	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. PLoS Pathogens, 2010, 6, e1001123.	4.7	108
18	Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection. Journal of Virology, 2006, 80, 11094-11104.	3.4	103

#	Article	IF	Citations
19	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. Journal of Hepatology, 2017, 66, 297-303.	3.7	101
20	TheHCP5Singleâ€Nucleotide Polymorphism: A Simple Screening Tool for Prediction of Hypersensitivity Reaction to Abacavir. Journal of Infectious Diseases, 2008, 198, 864-867.	4.0	90
21	Incidence and Risk Factors for Chronic Elevation of Alanine Aminotransferase Levels in HIVâ€Infected Persons without Hepatitis B or C Virus Coâ€Infection. Clinical Infectious Diseases, 2010, 50, 502-511.	5.8	88
22	Quantitative PCR to diagnosePneumocystispneumonia in immunocompromised non-HIV patients. European Respiratory Journal, 2012, 39, 971-978.	6.7	84
23	Hepatitis C virus transmission among human immunodeficiency virusâ€infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. Hepatology, 2016, 64, 1856-1869.	7.3	82
24	Host and Viral Genetic Correlates of Clinical Definitions of HIV-1 Disease Progression. PLoS ONE, 2010, 5, e11079.	2.5	78
25	Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna. Antiviral Therapy, 2011, 16, 535-545.	1.0	77
26	Highlights of the 2017 European <scp>AIDS</scp> Clinical Society (EACS) Guidelines for the treatment of adult <scp>HIV</scp>â€positive persons version 9.0. HIV Medicine, 2018, 19, 309-315.	2.2	77
27	Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. Aids, 2009, 23, 1689-1699.	2.2	69
28	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). International Journal of Epidemiology, 2022, 51, 33-34j.	1.9	69
29	Hepatitis B Virus Infection Is Associated With Impaired Immunological Recovery During Antiretroviral Therapy in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2013, 208, 1454-1458.	4.0	67
30	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. Annals of Internal Medicine, 2021, 174, 758-767.	3.9	66
31	Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. Gut, 2015, 64, 813-819.	12.1	65
32	Tracking Virus-Specific CD4+ T Cells during and after Acute Hepatitis C Virus Infection. PLoS ONE, 2007, 2, e649.	2.5	65
33	Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics, 2009, 10, 1819-1837.	1.3	64
34	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology, 2009, 50, 1017-1029.	7.3	60
35	Effect of immune pressure on hepatitis C virus evolution: Insights from a single-source outbreak. Hepatology, 2011, 53, 396-405.	7.3	60
36	Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. HIV Medicine, 2022, 23, 849-858.	2.2	57

#	Article	IF	Citations
37	Estimating the net contribution of interleukinâ€28B variation to spontaneous hepatitis C virus clearance. Hepatology, 2011, 53, 1446-1454.	7.3	56
38	Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons. Clinical Infectious Diseases, 2013, 57, 112-121.	5.8	56
39	A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). Aids, 2011, 25, 1481-1487.	2.2	55
40	Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B. Clinical Infectious Diseases, 2011, 53, 1143-1152.	5.8	53
41	Disentangling Human Tolerance and Resistance Against HIV. PLoS Biology, 2014, 12, e1001951.	5.6	53
42	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virusâ€“coinfected Individuals From 2001 to 2014: A Multicohort Study. Clinical Infectious Diseases, 2016, 63, 821-829.	5.8	48
43	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. Nature, 2018, 561, 406-410.	27.8	47
44	A Treatment-as-Prevention Trial to Eliminate Hepatitis C Among Men Who Have Sex With Men Living With Human Immunodeficiency Virus (HIV) in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 73, e2194-e2202.	5.8	47
45	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut, 2010, 59, 1252-1258.	12.1	46
46	High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. Journal of Hepatology, 2015, 63, 573-580.	3.7	46
47	Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017. HIV Medicine, 2020, 21, 228-239.	2.2	46
48	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. PLoS ONE, 2011, 6, e27463.	2.5	46
49	Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection. Tissue Antigens, 2007, 69, 237-240.	1.0	45
50	A validated assay by liquid chromatographyâ€“tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. Journal of Mass Spectrometry, 2013, 48, 616-625.	1.6	45
51	Chronic Hepatitis C in HIV-Infected Patients: Low Eligibility and Applicability of Therapy With Pegylated Interferon-?? Plus Ribavirin. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 238-240.	2.1	41
52	Linkage and retention in <scp>HCV</scp> care for <scp>HIV</scp>â€infected populations: early data from the <scp>DAA</scp> era. Journal of the International AIDS Society, 2018, 21, e25051.	3.0	40
53	Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. Open Forum Infectious Diseases, 2015, 2, ofv108.	0.9	38
54	Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy. PLoS ONE, 2015, 10, e0138838.	2.5	38

#	Article	IF	Citations
55	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. Molecular Biology and Evolution, 2018, 35, 27-37.	8.9	37
56	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. International Journal of Epidemiology, 2014, 43, 887-896.	1.9	36
57	A randomized crossover study to compare efavirenz and etravirine treatment. Aids, 2011, 25, 57-63.	2.2	34
58	Parvovirus 4 Infection and Clinical Outcome in High-Risk Populations. Journal of Infectious Diseases, 2012, 205, 1816-1820.	4.0	34
59	Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2017, 64, ciw809.	5.8	34
60	Hepatitis C: a changing epidemic. Swiss Medical Weekly, 2015, 145, w14093.	1.6	32
61	Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. Journal of Hepatology, 2019, 71, 274-280.	3.7	31
62	CD4⁺T Cell Count Decreases by Ethnicity among Untreated Patients with HIV Infection in South Africa and Switzerland. Journal of Infectious Diseases, 2009, 200, 1729-1735.	4.0	30
63	High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virusâ€“coinfected Men Who Have Sex With Men. Clinical Infectious Diseases, 2019, 68, 569-576.	5.8	30
64	Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity In Vivo. Journal of Virology, 2014, 88, 763-767.	3.4	29
65	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. Journal of Experimental Medicine, 2018, 215, 1589-1608.	8.5	29
66	Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study. Antiviral Therapy, 2008, 13, 1019-1028.	1.0	29
67	HLAâ€Bw4Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 46, 1921-1925.	5.8	28
68	The recent breakthroughs in the understanding of host genomics in hepatitis C. European Journal of Clinical Investigation, 2010, 40, 950-959.	3.4	28
69	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. Journal of Infectious Diseases, 2019, 220, 254-265.	4.0	27
70	Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. Aids, 2021, 35, 869-882.	2.2	27
71	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment ofÂrecently acquired hepatitis C infection. Journal of Hepatology, 2021, 75, 829-839.	3.7	27
72	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. Scientific Reports, 2022, 12, 577.	3.3	27

#	Article	IF	Citations
73	Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men. Journal of Hepatology, 2016, 65, 26-32.	3.7	26
74	Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial. Clinical Infectious Diseases, 2022, 75, e585-e593.	5.8	26
75	Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. PLoS ONE, 2013, 8, e64283.	2.5	25
76	Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in Switzerland. American Journal of Epidemiology, 2014, 179, 1514-1525.	3.4	25
77	Hepatitis B viral load in dried blood spots: A validation study in Zambia. Journal of Clinical Virology, 2015, 72, 20-24.	3.1	25
78	HLA-Bâˆ—27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope. Journal of Hepatology, 2014, 60, 22-29.	3.7	24
79	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. Aids, 2018, 32, 1995-2004.	2.2	24
80	Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era. Journal of Infectious Diseases, 2019, 220, 91-99.	4.0	24
81	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 240-250.	2.1	24
82	Genetic Variations in IL28B and Allergic Disease in Children. PLoS ONE, 2012, 7, e30607.	2.5	23
83	Molecular Analyses Define VÎ±7.2-JÎ±33+ MAIT Cell Depletion in HIV Infection. Medicine (United States), 2015, 94, e1134.	1.0	23
84	Clinical Course, Radiological Manifestations, and Outcome of Pneumocystis jirovecii Pneumonia in HIV Patients and Renal Transplant Recipients. PLoS ONE, 2016, 11, e0164320.	2.5	23
85	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. Clinical Infectious Diseases, 2017, 64, 1275-1278.	5.8	23
86	HLA-B*57:01+ abacavir-naive individuals have specific T cells but no patch test reactivity. Journal of Allergy and Clinical Immunology, 2013, 132, 756-758.	2.9	22
87	Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. Antimicrobial Agents and Chemotherapy, 2013, 57, 3147-3158.	3.2	22
88	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. Journal of Infectious Diseases, 2020, 222, 637-645.	4.0	22
89	Trends in <scp>HCV</scp> treatment uptake, efficacy and impact on liver fibrosis in the Swiss <scp>HIV</scp> Cohort Study. Liver International, 2018, 38, 424-431.	3.9	22
90	Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel. Aids, 2020, 34, 1699-1711.	2.2	21

#	Article	IF	Citations
91	Constrained Pattern of Viral Evolution in Acute and Early HCV Infection Limits Viral Plasticity. PLoS ONE, 2011, 6, e16797.	2.5	21
92	Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again. Pharmacogenomics, 2006, 7, 15-23.	1.3	20
93	Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis. AIDS and Behavior, 2012, 16, 245-255.	2.7	20
94	Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. Open Forum Infectious Diseases, 2015, 2, ofv026.	0.9	20
95	A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15Âyears after exposure. BMC Infectious Diseases, 2017, 17, 81.	2.9	20
96	On the potential of a shortâ€term intensive intervention to interrupt HCV transmission in HIVâ€positive men who have sex with men: A mathematical modelling study. Journal of Viral Hepatitis, 2018, 25, 10-18.	2.0	20
97	Hepatitis C in HIVâ€infected individuals: a systematic review and metaâ€analysis of estimated prevalence in Africa. Journal of the International AIDS Society, 2016, 19, 20711.	3.0	19
98	New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals. Human Immunology, 2020, 81, 300-304.	2.4	19
99	Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression. Aids, 2014, 28, 1261-1272.	2.2	18
100	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. PLoS ONE, 2015, 10, e0133028.	2.5	18
101	Liver fibrosis in treatment-naÃ¯ve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared. International Journal of Infectious Diseases, 2016, 51, 97-102.	3.3	18
102	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. Virus Evolution, 2018, 4, vey024.	4.9	17
103	Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2018, 5, ofy154.	0.9	17
104	Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. Journal of Infectious Diseases, 2014, 210, 1555-1561.	4.0	16
105	Evidence of CD4+ T cell-mediated immune pressure on the Hepatitis C virus genome. Scientific Reports, 2018, 8, 7224.	3.3	16
106	Viral escape in the CNS with multidrug-resistant HIV-1. Journal of the International AIDS Society, 2014, 17, 19745.	3.0	15
107	Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men. Infectious Disease Clinics of North America, 2018, 32, 395-405.	5.1	15
108	Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in subâ€Saharan Africa: Systematic review and metaâ€analysis. Liver International, 2021, 41, 710-719.	3.9	15

#	Article	IF	Citations
109	Low Current and Nadir CD4⁺ T-Cell Counts are Associated with Higher Hepatitis C virus RNA Levels in the Swiss HIV Cohort Study. Antiviral Therapy, 2008, 13, 455-460.	1.0	15
110	Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study: A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program. Clinical Infectious Diseases, 2022, 75, 1723-1731.	5.8	14
111	Efficacy of leadâ€in silibinin and subsequent triple therapy in difficultâ€toâ€treat <scp>HIV</scp>/hepatitis <scp>C</scp> virusâ€coinfected patients. HIV Medicine, 2014, 15, 625-630.	2.2	13
112	Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunctionâ€”A Prospective Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 227-232.	2.1	13
113	OUP accepted manuscript. Clinical Infectious Diseases, 2019, 68, 561-568.	5.8	13
114	Infrequent Replication of Parvovirus B19 and Erythrovirus Genotypes 2 and 3 among HIVâ€Infected Patients with Chronic Anemia. Clinical Infectious Diseases, 2010, 50, 115-118.	5.8	12
115	Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men. HIV Medicine, 2018, 19, 420-425.	2.2	12
116	Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Medical Weekly, 2017, 147, w14543.	1.6	12
117	Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland. Journal of Virus Eradication, 2016, 2, 52-4.	0.5	12
118	Changes in Biomarkers of Liver Disease during Successful Combination Antiretroviral Therapy in HIVâ€“HCV-Coinfected Individuals. Antiviral Therapy, 2014, 19, 149-159.	1.0	11
119	Intestinal colonisation with extended-spectrum cephalosporin-resistant Enterobacteriaceae in different populations in Switzerland: prevalence, risk factors and molecular features. Journal of Global Antimicrobial Resistance, 2018, 12, 17-19.	2.2	11
120	Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 Among Human Immunodeficiency Virusâ€“positive Gay and Bisexual Men?. Clinical Infectious Diseases, 2020, 70, 106-113.	5.8	11
121	The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. Journal of Clinical Medicine, 2021, 10, 295.	2.4	11
122	No Effect of Pegylated Interferon-Î± on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients. Journal of Infectious Diseases, 2018, 217, 1883-1888.	4.0	10
123	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. Clinical Infectious Diseases, 2021, 72, 2175-2183.	5.8	10
124	Dysphagia in Elderly Women: Consider Tetanus. Infection, 2006, 34, 35-38.	4.7	9
125	How reliable is an undetectable viral load?. HIV Medicine, 2009, 10, 470-476.	2.2	9
126	Intestinal colonisation with extended-spectrum cephalosporin- and colistin-resistant Enterobacteriaceae in HIV-positive individuals in Switzerland: molecular features and risk factors. International Journal of Antimicrobial Agents, 2017, 49, 519-521.	2.5	9

#	Article	IF	Citations
127	Clusters of Sexual Behavior in Human Immunodeficiency Virusâ€“positive Men Who Have Sex With Men Reveal Highly Dissimilar Time Trends. Clinical Infectious Diseases, 2019, 70, 416-424.	5.8	9
128	Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviralâ€naÃ¯ve persons starting treatment. HIV Medicine, 2020, 21, 599-606.	2.2	9
129	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines ComirnatyÂ® and COVID-19 mRNA Vaccine ModernaÂ®. Trials, 2021, 22, 724.	1.6	9
130	Viral Escape in the Central Nervous System with Multidrug-Resistant Human Immunodeficiency Virus-1. Open Forum Infectious Diseases, 2016, 3, ofv210.	0.9	8
131	The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. Open Forum Infectious Diseases, 2018, 5, ofy078.	0.9	8
132	The influence of human genetic variation on Epsteinâ€“Barr virus sequence diversity. Scientific Reports, 2021, 11, 4586.	3.3	8
133	Low Levels of Mannan-Binding Lectin or Ficolins Are Not Associated with an Increased Risk of Cytomegalovirus Disease in HIV-Infected Patients. PLoS ONE, 2013, 8, e51983.	2.5	8
134	Effect of Hepatitis C Treatment on Cd4⁺T-C El L Counts And The Risk Of Death In HIVâ€“HCV-Coinfected Patients: The Cohere Collaboration. Antiviral Therapy, 2012, 17, 1541-1550.	1.0	7
135	Role of MicroRNA Modulation in the Interferon-Î±/Ribavirin Suppression of HIV-1 In Vivo. PLoS ONE, 2014, 9, e109220.	2.5	7
136	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 517-524.	2.1	7
137	Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study. Antiviral Therapy, 2008, 13, 455-60.	1.0	7
138	Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antiviral Therapy, 2008, 13, 1019-28.	1.0	7
139	Quantifying the drivers of <scp>HIV</scp> transmission and prevention in men who have sex with men: a population modelâ€based analysis in Switzerland. HIV Medicine, 2018, 19, 688-697.	2.2	6
140	Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. BMC Infectious Diseases, 2019, 19, 834.	2.9	6
141	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. Journal of Infectious Diseases, 2019, 220, 244-253.	4.0	6
142	Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. PLoS Computational Biology, 2021, 17, e1009529.	3.2	6
143	Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. Aids, 2011, 25, 2306-2308.	2.2	5
144	Expansion of interferonâ€Î³â€secreting <scp>HIV</scp>â€specific T cells during successful antiretroviral therapy. HIV Medicine, 2013, 14, 241-246.	2.2	5

#	Article	IF	Citations
145	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. Antiviral Therapy, 2015, 20, 261-269.	1.0	5
146	Protease inhibitors to treat hepatitis <scp>C</scp> in the <scp>S</scp>wiss <scp>HIV C</scp>ohort <scp>S</scp>tudy: high efficacy but low treatment uptake. HIV Medicine, 2015, 16, 599-607.	2.2	5
147	Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity. Open Forum Infectious Diseases, 2018, 5, ofy275.	0.9	5
148	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. Journal of Infectious Diseases, 2020, 224, 1198-1208.	4.0	5
149	Hepatitis C among men who have sex with men: knowing your epidemic. The Lancet Gastroenterology and Hepatology, 2021, 6, 5-6.	8.1	5
150	Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. PLoS ONE, 2015, 10, e0133879.	2.5	5
151	Imaging patterns of Pneumocystis jirovecii pneumonia in HIV-positive and renal transplant patients â€“ a multicentre study. Swiss Medical Weekly, 2019, 149, w20130.	1.6	5
152	Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance. Antiviral Therapy, 2009, 14, 953-964.	1.0	4
153	Impact of a Nurse Vaccination Program on Hepatitis B Immunity in a Swiss HIV Clinic. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 472-474.	2.1	4
154	Fewer pills do not mean fewer drugâ€“drug interactions. Aids, 2018, 32, 676-678.	2.2	4
155	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. Haematologica, 2021, 106, 2233-2241.	3.5	4
156	Heterogeneity in testing practices for infections during pregnancy: national survey across Switzerland. Swiss Medical Weekly, 2016, 146, w14325.	1.6	4
157	How do healthcare providers construe patient complexity? A qualitative study of multimorbidity in HIV outpatient clinical practice. BMJ Open, 2021, 11, e051013.	1.9	4
158	Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons. Aids, 2020, 34, 1485-1495.	2.2	3
159	HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. Viruses, 2020, 12, 1241.	3.3	3
160	A systematic molecular epidemiology screen reveals numerous HIV-1 superinfections in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, , .	4.0	3
161	Personalized hepatitis C therapy: opportunities and pitfalls. Expert Review of Molecular Diagnostics, 2011, 11, 127-129.	3.1	2
162	<scp>HLA</scp>â€<scp>Bw4</scp> identifies a population of <scp>HIV</scp>â€infected patients with an increased capacity to control viral replication after structured treatment interruption. HIV Medicine, 2012, 13, 589-595.	2.2	2

#	Article	IF	Citations
163	Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient. Aids, 2016, 30, 530-533.	2.2	2
164	An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters. Viruses, 2022, 14, 784.	3.3	2
165	Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia. BMJ Open Gastroenterology, 2022, 9, e000945.	2.7	2
166	A Bayesian network approach to study host and viral genetic correlates of HIV-1 disease progression. Retrovirology, 2011, 8, .	2.0	1
167	[784] EXHAUSTION OF VIRUS SPECIFIC CD4+ T CELLS DURING ACUTE HEPATITIS C. Journal of Hepatology, 2007, 46, S295.	3.7	0
168	Impact of IL28B Genotype on First-Week Response to Telaprevir-Based Therapy in HIVâ€“HCV Coinfection. Antiviral Therapy, 2015, 20, 407-413.	1.0	0
169	Recurrent Inflammatory Flares in HIV-Infected Patients: Consider Castleman Disease!. Journal of Investigative Medicine High Impact Case Reports, 2017, 5, 232470961772509.	0.6	0
170	Hepatitis C Virus Infection and HIV. , 2015, , 1-9.		0
171	Hepatitis C Virus Infection and HIV. , 2018, , 625-633.		0